Role of activated nuclear factor-κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck

Head and Neck

Volumn 29, Issue 10, 2007, Pages 959-971

  Allen, Clint T ^a   Ricker, Justin L ^a   Chen, Zhong ^a   Van Waes, Carter ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

Author keywords

Bortezomib; EGFR; Head and neck squamous cell carcinoma; Nuclear factor B; Signal transduction

Indexed keywords

ATM PROTEIN; BCL2 RELATED PROTEIN A1; CHEMOKINE RECEPTOR CCR7; CYCLIN D1; GELATINASE B; GENE PRODUCT; GLYCOPROTEIN P; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HEPARIN LYASE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN BCL XL; PROTEIN MDM2; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNINDEXED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; GENE EXPRESSION; GENE TARGETING; HEAD AND NECK CARCINOMA; HUMAN; INFLAMMATION; ONCOGENE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; CANCER INVASION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE COURSE; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; HEAD AND NECK TUMOR; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; INFLAMMATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; ONCOGENES;

EID: 38449103501     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20615     Document Type: Review

References (110)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Posner MR. Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy. Oncologist 2005;10(Suppl 3):11-19.
3. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
4. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-1900.
5. Mao L, Hong WK, Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer Cell 2004;5:311-316.
6. Greten FR, Karin M. The IKK/NF-κB activation pathway - a target for prevention and treatment of cancer. Cancer Lett 2004;206:193-199.
7. Chen Z, Malhotra PS, Thomas GR, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999;5:1369-1379.
8. Ondrey FG, Dong G, Sunwoo J, et al. Constitutive activation of transcription factors NF-(κ)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 1999;26:119-129.
9. Zhang PL, Pellitteri PK, Law A, et al. Overexpression of phosphorylated nuclear factor-κ B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis. Mod Pathol 2005;18:924-932.
10. Loercher A, Lee TL, Ricker JL, et al. Nuclear factor-κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004;64:6511-6523.
11. Dong G, Chen Z, Kato T, Van Waes C. The host environment promotes the constitutive activation of nuclear factor-κB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res 1999;59:3495-3504.
12. Kato T, Duffey DC, Ondrey FG, et al. Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-κB. Head Neck 2000;22:748-759.
13. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999;5:412-417.
14. Qing G, Xiao G. Essential role of IκB kinase α in the constitutive processing of NF-κB2 p100. J Biol Chem 2005;280:9765-9768.
15. Luo JL, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 2005;115:2625-2632.
16. Li ZW, Chu W, Hu Y, et al. The IKKβ subunit of IκB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis. J Exp Med 1999;189:1839-1845.
17. Sizemore N, Lerner N, Dombrowski N, Sakurai H, Stark GR. Distinct roles of the I kappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from I kappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem 2002;277:3863-3869.
18. Chang AA, Van Waes C. Nuclear factor-κB as a common target and activator of oncogenes in head and neck squamous cell carcinoma. Adv Otorhinolaryngol 2005;62:92-102.
19. Senftleben U, Cao Y, Xiao G, et al. Activation by IKKα of a second, evolutionary conserved, NF-κ B signaling pathway. Science 2001;293:1495-1499.
20. Xiao G, Harhaj EW, Sun SC. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol Cell 2001;7:401-409.
21. Chen ZJ. Ubiquitin signalling in the NF-κB pathway. Nat Cell Biol 2005;7:758-765.
22. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986;46:705-716.
23. Gilmore TD. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene 1999;18:6925-6937.
24. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999;18:6853-6866.
25. Capaccio P, Pruneri G, Carboni N, et al. Cyclin D1 expression is predictive of occult metastases in head and neck cancer patients with clinically negative cervical lymph nodes. Head Neck 2000;22:234-240.
26. Namazie A, Alavi S, Olopade OI, et al. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope 2002;112:472-481.
27. Bartkova J, Lukas J, Muller H, Strauss M, Gusterson B, Bartek J. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 1995;55:949-956.
28. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999;19:5785-5799.
29. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-κB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 1999;19:2690-2698.
30. Van Waes C, Chang AA, Lebowitz PF, et al. Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005;63:1400-1412.
31. Barkett M, Gilmore TD. Control of apoptosis by Rel/ NF-κB transcription factors. Oncogene 1999;18:6910-6924.
32. Briskin KB, Fady C, Wang M, Lichtenstein A. Apoptotic inhibition of head and neck squamous cell carcinoma cells by tumor necrosis factor α. Arch Otolaryngol Head Neck Surg 1996;122:559-563.
33. Duffey DC, Crowl-Bancroft CV, Chen Z, et al. Inhibition of transcription factor nuclear factor-κB by a mutant inhibitor-κBα attenuates resistance of human head and neck squamous cell carcinoma to TNF-α caspase-mediated cell death. Br J Cancer 2000;83:1367-1374.
34. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-1683.
35. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis. Genes Dev 1999;13:382-387.
36. Trask DK, Wolf GT, Bradford CR, et al. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope 2002;112: 638-644.
37. Duffey DC, Chen Z, Dong G, et al. Expression of a dominant-negative mutant inhibitor-κBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999;59:3468-3474.
38. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 2003;63:2948-2956.
39. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000;19:2489-2495.
40. Lee TL, Yeh J, Van Waes C, Chen Z. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/ or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 2006;5:8-19.
41. Hong SH, Ondrey FG, Avis IM, et al. Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation? FASEB J 2000;14:1499-1507.
42. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I. p53 stabilization is decreased upon NFκB activation: a role for NFκB in acquisition of resistance to chemotherapy. Cancer Cell 2002;1:493-503.
43. Rocha S, Garrett MD, Campbell KJ, Schumm K, Perkins ND. Regulation of NF-κB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J 2005;24:1157-1169.
44. Gurova KV, Hill JE, Guo C, et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-κB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A 2005;102:17448-17453.
45. Li N, Karin M. Ionizing radiation and short wavelength UV activate NF-κB through two distinct mechanisms. Proc Natl Acad Sci U S A 1998;95:13012-13017.
46. Uno M, Otsuki T, Hiratsuka J, et al. Expression of cell cycle regulator genes in KB, a human squamous cell carcinoma cell line, after irradiation. Int J Oncol 2000;17:947-954.
47. Zerbini LF, Wang Y, Czibere A, et al. NF-κ B-mediated repression of growth arrest- and DNA-damage-inducible proteins 45α and γ is essential for cancer cell survival. Proc Natl Acad Sci U S A 2004;101:13618-13623.
48. Ying J, Srivastava G, Hsieh WS, et al. The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. Clin Cancer Res 2005;11:6442-6449.
49. Kim KM, Zhang Y, Kim BY, et al. The p65 subunit of nuclear factor-κB is a molecular target for radiation sensitization of human squamous carcinoma cells. Mol Cancer Ther 2004;3:693-698.
50. Callaghan R, Ford RC, Kerr ID. The translocation mechanism of P-glycoprotein. FEBS Lett 2006;580:1056-1063.
51. Bentires-Alj M, Barbu V, Fillet M, et al. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003;22:90-97.
52. Dong QG, Sclabas GM, Fujioka S, et al. The function of multiple IκB: NF-κB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 2002;21:6510-6519.
53. Dong G, Loukinova E, Chen Z, et al. Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-κB signal pathway. Cancer Res 2001;61:4797-4808.
54. Nishimura T, Newkirk K, Sessions RB, et al. Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 1996;2:1859-1865.
55. Kondo T, Higashiyama Y, Goto S, et al. Regulation of γ- glutamylcysteine synthetase expression in response to oxidative stress. Free Radic Res 1999;31:325-334.
56. Wolf JS, Chen Z, Dong G, et al. IL (interleukin)-1α promotes nuclear factor-κB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 2001;7:1812-1820.
57. Shintani S, Ishikawa T, Nonaka T, et al. Growth-regulated oncogene-1 expression is associated with angiogenesis and lymph node metastasis in human oral cancer. Oncology 2004;66:316-322.
58. Bancroft CC, Chen Z, Dong G, et al. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-κB signal pathways. Clin Cancer Res 2001;7:435-442.
59. Riedel F, Gotte K, Schwalb J, Wirtz H, Bergler W, Hormann K. Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Otorhinolaryngol 2000;257:332-336.
60. Bancroft CC, Chen Z, Yeh J, et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002;99:538-548.
61. Ruan HY, Masuda M, Ito A, et al. Effects of a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines. Head Neck 2006;28:158-165.
62. Chilov D, Kukk E, Taira S, et al. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem 1997;272:25176-25183.
63. Druzgal CH, Chen Z, Yeh NT, et al. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. Head Neck 2005;27:771-784.
64. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-κ B. FEBS Lett 1998;435:29-34.
65. O-Charoenrat P, Rhys-Evans PH, Eccles SA. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001;127:813-820.
66. Riedel F, Gotte K, Schwalb J, Bergler W, Hormann K. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol 2000;17:1099-1105.
67. Andela VB, Schwarz EM, Puzas JE, O'Keefe RJ, Rosier RN. Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor κB. Cancer Res 2000;60:6557-6562.
68. Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev 1999;18:345-357.
69. Biolchini F, Pollastri G, Figurelli S, Chiarini L. Carcinogen metabolism, DNA damage repair and oral head and neck squamocellular carcinoma (HNSCC). A review. Minerva Stomatol 2005;54:405-414.
70. Anto RJ, Mukhopadhyay A, Shishodia S, Gairola CG, Aggarwal BB. Cigarette smoke condensate activates nuclear transcription factor-κB through phosphorylation and degradation of IκB(α): correlation with induction of cyclooxygenase-2. Carcinogenesis 2002;23:1511-1518.
71. Lin SC, Lu SY, Lee SY, Lin CY, Chen CH, Chang KW. Areca (betel) nut extract activates mitogen-activated protein kinasesand NF-κB in oral keratinocytes. Int J Cancer 2005;116:526-535.
72. Chung JY, Park YC, Ye H, Wu H. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 2002;115(Part 4):679-688.
73. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001;412:346-351.
74. Chen Z, Colon I, Ortiz N, et al. Effects of interleukin-1α, interleukin-1 receptor antagonist, and neutralizing antibody on proinflammatory cytokine expression by human squamous cell carcinoma lines. Cancer Res 1998;58:3668-3676.
75. von Biberstein SE, Spiro JD, Lindquist R, Kreutzer DL. Enhanced tumor cell expression of tumor necrosis factor receptors in head and neck squamous cell carcinoma. Am J Surg 1995;170:416-422.
76. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
77. Grandis JR, Tweardy DJ. TGF-α and EGFR in head and neck cancer. J Cell Biochem Suppl 1993;17F:188-191.
78. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004;102:37-46.
79. Wang J, Zhang X, Thomas SM, et al. Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene 2005;24:5897-5904.
80. Wang J, Xi L, Hunt JL, et al. Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res 2004;64:1861-1866.
81. Tanaka H, Fujita N, Tsuruo T. 3-Phosphoinositide-dependent protein kinase-1-mediated IκB kinase β (IkkB) phosphorylation activates NF-κB signaling. J Biol Chem 2005;280:40965-40973.
82. Tamatani T, Azuma M, Aota K, Yamashita T, Bando T, Sato M. Enhanced IκB kinase activity is responsible for the augmented activity of NF-κB in human head and neck carcinoma cells. Cancer Lett 2001;171:165-172.
83. Nakayama H, Ikebe T, Beppu M, Shirasuna K. High expression levels of nuclear factor κB, IκB kinase a and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 2001;92:3037-3044.
84. Pedrero JM, Carracedo DG, Pinto CM, et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/ PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 2005;114:242-248.
85. McElhinny JA, Trushin SA, Bren GD, Chester N, Paya CV. Casein kinase II phosphorylates I κ B α at S-283, S-289, S-293, and T-291 and is required for its degradation. Mol Cell Biol 1996;16:899-906.
86. Wang D, Westerheide SD, Hanson JL, Baldwin AS Jr. Tumor necrosis factor α-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem 2000;275:32592-32597.
87. Kato T Jr, Delhase M, Hoffmann A, Karin M. CK2 Is a C-terminal IαB kinase responsible for NF-αB activation during the UV response. Mol Cell 2003;12:829-839.
88. Gapany M, Faust RA, Tawfic S, Davis A, Adams GL, Ahmed K. Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck. Mol Med 1995;1:659-666.
89. Yu M, Yeh J, Van Waes C. Protein kinase casein kinase 2 mediates inhibitor-κB kinase and aberrant nuclear factor-κB activation by serum factor(s) in head and neck squamous carcinoma cells. Cancer Res 2006;66:6722-6731.
90. Hu Y, Baud V, Delhase M, et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKα subunit of IκB kinase. Science 1999;284:316-320.
91. Hiscott J, Kwon H, Genin P. Hostile takeovers: viral appropriation of the NF-κB pathway. J Clin Invest 2001;107:143-151.
92. Covert MW, Leung TH, Gaston JE, Baltimore D. Achieving stability of lipopolysaccharide-induced NF-κB activation. Science 2005;309:1854-1857.
93. Cummins EP, Taylor CT. Hypoxia-responsive transcription factors. Pflugers Arch 2005;450:363-371.
94. Hur GM, Lewis J, Yang Q, et al. The death domain kinase RIP has an essential role in DNA damage-induced NF-κ B activation. Genes Dev 2003;17:873-882.
95. Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S. Sequential modification of NEMO/IKKγ by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress. Cell 2003;115:565-576.
96. Janssens S, Tinel A, Lippens S, Tschopp J. PIDD mediates NF-κB activation in response to DNA damage. Cell 2005;123:1079-1092.
97. Epinat JC, Gilmore TD. Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway. Oncogene 1999;18:6896-6909.
98. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-2645.
99. Saunders G. Overview of drug therapy for multiple myeloma. J Oncol Pharm Pract 2005;11:83-100.
100. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-2622.
101. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κ B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419-1428.
102. Chang AA, Chen Z, Ricker JL, et al. Induction of apoptosis and regulation of inhibitor of apoptosis-1 protein and cyclin D1 expression in head and neck cancer cell lines by PS-241/bortezomib (VELCADE), a novel proteasome inhibitor. Proc Am Assoc Cancer Res 2004;95:4007.
103. Van Waes C, Sunwoo JB, DeGraff W, et al. Radiosensitization and proteasome inhibition. In: JA, editor. Cancer drug discovery and development: proteasome inhibitors in cancer therapy. Totowa, NJ: Humana; 2004. pp123-131.
104. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000;355:949-955.
105. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004;22:1743-1752.
106. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
107. Gupta AK, McKenna WG, Weber CN, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002;8:885-892.
108. Pomerantz RG, Grandis JR. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin Oncol 2004;31:734-743.
109. Hambek M, Baghi M, Baumaun H, et al. Iressa (ZD 1839) inhibits phosphorylation of three different downstream signal transducers in head and neck cancer (SCCHN). Anticancer Res 2005;25:1871-1875.
110. Song J, Chen C, Raben D. Emerging role of EGFR-targeted therapies and radiation in head and neck cancer. Oncology (Williston Park) 2004;18:1757-1767; discussion 1767, 1771-1772, 1777.